Diagnostics and therapeutics for diseases associated with kallikrein 13 (klk13)

A method of screening for therapeutic agents useful in the treatment of a disease selected from the group consisting of hematological diseases, neurological diseases, metabolic diseases, endocrinological diseases, dermatological diseases, gastroenterological diseases, urological diseases, cancer disorders and inflammation in a mammal comprising the steps of

• i) determining the activity of a KLK13 polypeptide at a certain concentration of a test compound or in the absence of said test compound, and
• ii) determining the activity of said polypeptide at a different concentration of said test compound.

A method of screening for therapeutic agents useful in the treatment of a disease selected from the group consisting of hematological diseases, neurological diseases, metabolic diseases, endocrinological diseases, dermatological diseases, gastroenterological diseases, urological diseases, cancer disorders and inflammation in a mammal comprising the steps of

• i) determining the activity of a KLK13 polypeptide at a certain concentration of a test compound, and
• ii) determining the activity of a KLK13 polypeptide at the presence of a compound known to be a regulator of a KLK13 polypeptide.

A method of screening for therapeutic agents useful in the treatment of a disease selected from the group consisting of hematological diseases, neurological diseases, metabolic diseases, endocrinological diseases, dermatological diseases, gastroenterological diseases, urological diseases, cancer disorders and inflammation in a mammal comprising the steps of

• i) contacting a test compound with a KLK13 polynucleotide, and
• ii) detecting binding of said test compound to said KLK13 polynucleotide.

A method of diagnosing a disease selected from the group consisting of hematological diseases, neurological diseases, metabolic diseases, endocrinological diseases, dermatological diseases, gastroenterological diseases, urological diseases, cancer disorders and inflammation in a mammal comprising the steps of

• i) determining the amount of a KLK13 polynucleotide in a sample taken from said mammal, and
• ii) determining the amount of KLK13 polynucleotide in healthy and/or diseased mammals.

19-20. (canceled)

A pharmaceutical composition for the treatment of a disease selected from the group consisting of hematological diseases, neurological diseases, metabolic diseases, endocrinological diseases, dermatological diseases, gastroenterological diseases, urological diseases, cancer disorders and inflammation in a mammal comprising a KLK13 polynucleotide.

A pharmaceutical composition for the treatment of a disease selected from the group consisting of hematological diseases, neurological diseases, metabolic diseases, endocrinological diseases, dermatological diseases, gastroenterological diseases, urological diseases, cancer disorders and inflammation in a mammal comprising a KLK13 polypeptide.

24-26. (canceled)